



Argos Therapeutics  
Investor Relations Department  
4233 Technology Drive  
Durham, NC 27704  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: ARGS**


Last Trade:	0.30
Trade Time:	3:59 PM ET Jul 20, 2017
Change:	0.00 (+0.675%)
Day Range	0.30 - 0.33
52-Week Range	0.29 - 7.08
Volume	1,945,569

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jun 22, 2017*

[Argos Therapeutics Announces Closing of \\$6.0 Million Secured Convertible Note Financing](#)

*Jun 16, 2017*

[Argos Therapeutics Announces \\$6,000,000 Secured Convertible Note Financing](#)

*May 10, 2017*

[Argos Provides Update on its ADAPT Trial Following Meeting with FDA](#)

*Apr 18, 2017*

[Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial](#)

*Feb 22, 2017*

[Independent Data Monitoring Committee Recommends Discontinuation of the ADAPT Phase 3 Clinical Trial of Rocabudencel-T in Metastatic Renal Cell Carcinoma for Futility Following Its Planned Interim Data Review](#)

## Financials [\[ View all \]](#)

*Mar 16, 2017*

[Annual Report \(10-K\)](#)

*Jul 6, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 10, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 14, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 15, 2016*

[Quarterly Report \(10-Q\)](#)